We have recently shown that the dual inhibitor of BTK and HCK, KIN-8194, potently reduced the viability of ABC-DLBCL and WM cells harboring the pathogenic Myd88-L265P mutation [22]. This evidence concerns the gene BTK and diffuse large B-cell lymphoma.